**GOALS**

- A1C Goal: < 7-8% - personalize based on patient factors (See Attachment 1)
- Blood Sugar: Fix the fasting first (goal glucose 80-120 mg/dl)
  Then fix pre-prandial (goal glucose 80-120 mg/dl)
  Then fix post-prandial (goal glucose ≤ 180 mg/dl)
- Blood Pressure (BP) < 140/90 Lower target for some patients (See page 5)
- Statin treatment goal based on age and presence of known Atherosclerotic Cardiovascular Disease (ASCVD). (See page 6)

**DIAGNOSTIC CRITERIA**

<table>
<thead>
<tr>
<th>Test</th>
<th>Pre-Diabetes</th>
<th>Diabetes (DM)</th>
<th>Gestational Diabetes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fasting Plasma Glucose*</td>
<td>100 - 125 mg/dl</td>
<td>≥ 126 mg/dl</td>
<td>≥ 92 mg/dl</td>
</tr>
<tr>
<td>Random Plasma Glucose</td>
<td>-</td>
<td>≥ 200 mg/dl</td>
<td>-</td>
</tr>
</tbody>
</table>

*In the absence of unequivocal hyperglycemia, results should be confirmed by repeat testing. Only diagnostic in a patient with classic symptoms of hyperglycemia or hyperglycemic crisis.

**INITIAL EVALUATION**

**History**
- Complete clinical history including Cardiovascular Risk (CV) Factors and 10 year CV risk calculation (See page 8)
- End organ sequelae: Retinopathy, nephropathy, neuropathy, ASCVD, Peripheral Vascular Disease (PVD), Cerebrovascular Disease

**Physical Exam**
- Vitals: especially BP and Body Mass Index (BMI)
- Fundoscopic (Ensure screening done)
- Cardiovascular

**Diagnostics**
- Baseline A1C
- Fasting lipid panel
- Spot urine Albumin to Creatinine ratio
- Creatinine (Cr)
- TSH
- Fingerstick blood sugar (FSBS) logs
- Symptoms of hypoglycemia
- Patient self-management capacity
- Medications
- Patient concerns/compliance with meds
- Peripheral vascular – pulses
- Foot exam – quick check for wound risk, comprehensive monofilament test annually (See Attachment 2, page 18)

**TREATMENT OPTIONS**

**Therapeutic Lifestyle Changes:** The basis of treatment for all patients (See page 4)

**Medications:** See Algorithms pages 2-3

- Step 1: Metformin
- Step 2: Sulfonylurea, Pioglitazone, Basal Insulin
  (Patients with known ASCVD see page 6)
- Step 3: Basal Insulin, if not already on, then add:
  i. 1 dose regular insulin with largest meal, or other (See page 3)
  ii. 2 doses of regular insulin with meals
  iii. Adjust insulin based on post-prandial blood sugars
- Step 4: Consider alternative medication classes GLP-1, SGLT2, or DPP-4 if all nonformulary requirements are met

**MONITORING**

- PCP/Care Team visits as clinically appropriate
- A1C at goal: at least every 180 days, or as clinically appropriate
- A1C NOT at goal: at least every 90 days – more frequently if actively titrating meds (See page 7)
- Watch for risk of Clinical Inertia: Set goals, actively titrate until at goal

---

**TABLE OF CONTENTS**

- Pharmacologic Therapy Algorithm
- Insulin Algorithm
- Treatment Options
- Clinical Inertia
- Hypertension– Treatment and BP Goals
- Lipid Management
- Monitoring: Exams and Labs
- Preventive Care: Vaccines and Screenings
- Diabetic Nephropathy Monitoring
- Chronic Kidney Disease and Diabetes
- Diabetic Foot Care
- Switching Between NPH and Insulin Glargine
- Role of Sliding Scale Insulin
- Antihyperglycemic Medication Characteristics
- Management of Hypoglycemia in CCHCS
- Oral Diabetic Medications
- Injectable Medications
- Setting Target for Glycemic Control
- Monofilament Testing
- Gestational Diabetes Mellitus
- ADA Evidence-Grading System
- Patient Education (Spanish)
- Patient Education (Spanish)

---

Information contained in the Care Guide is not a substitute for a health care professional’s clinical judgment. Evaluation and treatment should be tailored to the individual patient and the clinical circumstances. Furthermore, using this information will not guarantee a specific outcome for each patient. Refer to “Disclaimer Regarding Care Guides” for further clarification.
**PHARMACOLOGIC THERAPY IN TYPE 2 DM: 2018 ADA AND CCHCS RECOMMENDATIONS**

<table>
<thead>
<tr>
<th>Summary</th>
<th>Decision Support</th>
<th>Patient Education/Self Management</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>STEP 1</strong>&lt;br&gt;Monotherapy</td>
<td>- If A1C &lt; 9%, start here</td>
<td>Metformin</td>
</tr>
<tr>
<td></td>
<td>• Start 500 mg qd. Check FSBS. If not controlled, titrate q 3-7 days to max dose of 2500 mg qd.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Monitor B12 level periodically.</td>
<td></td>
</tr>
</tbody>
</table>

| **STEP 2**<br>Dual Therapy | - If A1C ≥ 9%, start here | |
| | **2 A. If NO ASCVD*** | Metformin + Metformin + Metformin |
| | | Sulfonylurea** or Pioglitazone (TZD) or Basal Insulin Long-acting |
| | | or |
| | **2 B. With Known ASCVD*** | Metformin + Metformin + Metformin |
| | | Sulfonylurea** or Pioglitazone (TZD) or Basal Insulin Long-acting |
| | | or |

| **STEP 3**<br>Triple Therapy | - If A1C ≥ 10%, start here | |
| | Metformin + Sulfonylurea** + Insulin | Metformin + Pioglitazone (TZD) + Insulin |
| | Start with basal, Lantus or NPH, and add Prandial insulin then adjust based on post-prandial blood sugar as needed (see page 3) | |
| | or | Metformin + Insulin (basal or 70/30 BID) + GLP-1 or SGLT2 or DPP-4† With Endocrinologist Recommendation (see page 4) |

**BOLD** = formulary medications

*ASCVD defined as coronary artery disease, cerebrovascular disease, or peripheral arterial disease of atherosclerotic origin.

Screening for CAD in asymptomatic patients is not recommended.

**Taper and stop sulfonylurea when starting insulin other than basal insulin.

1Adapted from ADA 2018, Diabetes Care Volume 41, Supplement 1, Figure 8.1, January 2018.
INSULIN ALGORITHM

FIX THE FASTING FIRST
Add AM BASAL INSULIN (GLARGINE)
10 units or 0.1-0.2 units/kg

- Check AM FSBS daily - then INCREASE glargine by 2 units every 3-7 days until at fasting blood sugar goal
- Once Fasting blood sugar is at goal, STOP the FSBS order
- Generally stop Sulfonylurea when starting insulin

Increase AM basal insulin by 2-units every 3-7 days until at fasting blood sugar is at goal or basal dose (Glargine) is higher than 40-60 U (0.5 U/kg)

Is Fasting Blood Sugar Fixed/at goal?

Is Fasting Blood Sugar Fixed/at goal?

Consider dividing AM basal insulin dose into BID basal dose
Then continue to increase the basal insulin dose 2 units every 3-7 days until Fasting is Fixed
Can split dose equally AM/PM.

Is Fasting Blood Sugar Fixed/at goal?

Intensify insulin regimen
Assess patient compliance
- Education
- Pharmacy Consult
- Dietary Consult

Is A1C at goal?

Continue to check A1C every 3 months.
If at goal at least twice, can check A1C every 6 months
If stable, no need for routine FSBS testing

If FASTING blood sugars are good, but the A1C is still high
See OPTIONS below and start additional insulin dose based on the highest blood sugar reading

Option 1
Confirm with patient that largest meal of the day is dinner
Add 4 units of regular insulin before dinner
Monitor FASTING blood sugar and titrate dose by 2 units* every 3-7 days until FASTING blood sugar at goal

Option 2
Change to premixed insulin NPH/Reg (70/30) BID
Take current dose of basal and divide this dose
2/3 AM, 1/3 pm or
1/2 AM, 1/2 PM
Monitor FASTING blood sugar and increase 2 units* every 3-7 days until FASTING blood sugar at goal

Option 3
Check pre-meal and pre-bedtime blood sugars for 3 days
Based on results (highest blood sugar):
- Add additional dose of insulin as below:
  - Pre-breakfast BS highest - Add 4 units Regular at breakfast
  - Pre-dinner BS highest - Add 4 units NPH at breakfast
  - Pre-bedtime BS glucose - Add 4 units Regular at dinner
Monitor FASTING blood sugar and increase 2 units* every 3-7 days until FASTING blood sugar at goal

Is A1C at goal?

If Fasting blood sugars are good, but the A1C is still high

Assess patient compliance
- Education
- Pharmacy Consult
- Dietary Consult

Test 2 hour post-prandial blood sugar and add regular before the meal(s) to control
Consider Non-formulary third tier medication and Endocrine referral

Is A1C at goal?

Continue to check A1C every 3 months.
If at goal at least twice, can check A1C every 6 months
If stable, no need for routine FSBS testing

A1C mg/dl
6 126
7 154
8 183
9 212
10 240
11 269
12 298

Correlation between A1C and mean plasma glucose on multiple testing

*Can increase by 4 units every 3-7 days if fasting blood sugar is >180 mg/dl
If hypoglycemia occurs or fasting blood sugar is <80 mg/dl reduce the dose by 4 units or 10% whichever is greater
Goal for FASTING blood sugar: 80-130 mg/dl
Goal for 2 hour post-prandial is <180 mg/dl

1ADA 2016; AACE/ACE 2017; EASD 2009; All recommend limiting basal total to 0.5U/kg due to ↑ risk of hypoglycemia without significant benefits in glycemic reduction. Source: Adapted from Standards of Medical Care in Diabetes 2015 American Diabetes Association: Position Statement. http://care.diabetesjournals.org (S43).
I. SETTING GLYCEMIC GOAL WITH PATIENT: Generally <7%, but can be <6.5% or <8.0 based on patient factors
(See Attachment 1, page 17)

II. EDUCATION AND THERAPEUTIC LIFESTYLE CHANGES:

Patient Self-Management

- All patients with DM should participate in DM self-management education/support to assist with implementing and sustaining skills and behaviors needed for ongoing self-management. [B]*

Nutrition

- Consider diet counseling (onsite or via telemedicine) to provide patients with practical tools for day-to-day meal choice selection and better food choices at canteen.
- Provide DM dietary patient handouts: From the Dietary page on Lifeline (http://lifeline/HealthCareOperations/MedicalServices/Dietary/Pages/Home.aspx) Under Quick Links on the right Select Diabetic Education Handouts

Weight loss

- If BMI ≥ 25 in patients with pre-diabetes or DM, establish a realistic weight loss goal at the time of diagnosis.
- Weight loss of 2 - 8 kg may provide clinical benefits to those with Type 2 DM, especially early in the disease process.

Exercise

- Ensure patients on insulin or insulin secretagogues (sulfonylureas) understand the possibility of hypoglycemia with ↑ activity.
- The ADA recommends: at least 150 minutes of moderate/vigorous intensity exercise, spread out over ≥ 3 days/wk with no more than 2 consecutive days without activity. If younger and more physically fit: at least 75 minutes/week of vigorous intensity or interval training may be sufficient. [B]*

Psychosocial/Mental Health

- Ensure depression or other mental health issues are addressed, especially if the patient is non-adherent.
- Involve and engage the patient, promote self management skills, explore fears, and consider case coordination.

III. MEDICATIONS (See pages 14-16):

Start medications promptly when lifestyle efforts are not sufficient in achieving or maintaining glycemic goals.
Titrating every 3-7 days until fasting blood sugar goal is reached then monitor A1C and adjust if not maintaining glycemic control goal.

Medication choice – see algorithm (Pharmacologic Therapy in Type 2 DM page 2).

Step 1: Metformin
Step 2: Add Sulfonylurea (Glipizide NOT Glyburide), or TZD (Pioglitazone), or Basal Insulin, (or if ASCVD, see page 2).
Step 3: Add Basal Insulin (if not already on) glargine (QD or BID), or NPH (BID), or 70/30 BID, if still not in control add:
- Prandial insulin at largest meal. If still not in control, add
- Prandial insulin at multiple meals. If still not in control, monitor
- Post-prandial glucose level and adjust prandial insulin

Step 4: Fourth-line DM medications – GLP-1 (Liraglutide) or SGLT2 (Empagaflozin or Canagliflozin) have some data suggesting lower cardiovascular mortality, may be considered in patients with established CV disease with endocrinologist referral (see below).

Nonformulary forth-line Diabetes Medications may be considered in patients with established CV disease:

Before prescribing the CCHCS preferred nonformulary medication (see below) ensure all of the following:
1. The patient has failed to reach goal with an adequate trial of maximally tolerated doses of oral medications, and at least three month trial of basal insulin and 1 dose daily of prandial insulin.
2. The patient has had consult with a Registered Dietitian.
3. The patient is engaging in lifestyle changes.
4. The patient has seen an endocrinologist who recommends one of the below classes/medications:
   - GLP-1 (Liraglutide),
   - SGLT2 (Empagaflozin), or
   - DPP-4 (Sitagliptin) (limited efficacy)

Note: These medication classes have limited long-term safety data and are nonformulary.

**Clinical Inertia:** The failure of health care providers to initiate or intensify therapy when indicated is a big problem in the management of diabetes and diabetes-related co-morbidities such as hypertension. Physician/Provider-, patient-, and health care-system-related factors all contribute.

**Physician/Provider factors:**
- Failure to set clear goals
- Failure to initiate treatment
- Failure to titrate treatment to achieve goals
- Failure to identify and manage comorbidities (i.e., depression)
- Reactive rather than proactive care

**Patient factors:**
- Denial that disease is serious; absence of symptoms
- Low health literacy
- Too many medications/medication side effects
- Poor communication between the physician and the patient
- Lack of trust in physician
- Depression or substance abuse

**Clinical Consequences of Clinical Inertia:**
- Delays in treatment intensification can negatively affect a patient’s prognosis and contribute to patients living with suboptimal glycemic blood pressure or lipid control for years, leading to adverse outcomes and increased risk of complications.

**Overcoming Clinical Inertia:**
- Engage with the patient regarding the progressive nature of Type 2 DM, and encourage lifestyle modification behaviors from beginning of diagnosis, and throughout treatment.
- Ensure the patient understands the goals of their treatment, are involved in managing their disease, and trust their care team’s medical recommendations.
- Use the Complete Care Model to engage entire team in managing/monitoring the patient’s Type 2 DM including BP and lipids.
- Have a care team member see the patient frequently when not at goal and titrate medication aggressively.

### Hypertension Management in Patients with Diabetes – 2018 ADA Recommendations

**Recommended Blood Pressure (BP) Goals**

<table>
<thead>
<tr>
<th>Recommendation for DM</th>
<th>BP Goal</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADA (2018) Most patients with DM</td>
<td>&lt; 140/90</td>
</tr>
<tr>
<td>Individuals at high risk of CVD</td>
<td>&lt; 130/80</td>
</tr>
<tr>
<td>JNC 8 (2014)</td>
<td>&lt; 140/90</td>
</tr>
<tr>
<td>ACC/AHA (2017)</td>
<td>&lt; 130/80</td>
</tr>
</tbody>
</table>

**Treatment Recommendations**

<table>
<thead>
<tr>
<th>Blood Pressure*</th>
<th>Treatment Modalities</th>
<th>Evidence</th>
<th>Anti-Hypertensive Medications for Type 2 DM</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt; 120/80</td>
<td>Lifestyle Changes (↓ Wt, Na, ETOH, ↑K+)</td>
<td>[B]</td>
<td>All four of these four first line agents are useful and effective [A] ACC/AHA Executive Summary&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>≥ 140/90</td>
<td>1 Med + Lifestyle Changes Prompt initiation</td>
<td>[A]</td>
<td>-ACEI or ARB if albuminuria present</td>
</tr>
<tr>
<td></td>
<td>Timely subsequent titration</td>
<td></td>
<td>-Calcium channel Blockers</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>-Thiazide-like diuretic</td>
</tr>
<tr>
<td>≥ 160/100</td>
<td>2 Med + Lifestyle Changes Prompt initiation</td>
<td>[A]</td>
<td>-DO NOT USE ACEI AND ARB SIMULTANEOUSLY. Do not use ACEI/ARB with direct renin inhibitors (currently only Aliskiren®) [A]</td>
</tr>
<tr>
<td></td>
<td>Timely subsequent titration</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*For diagnosis: only one blood pressure value has to be high, either systolic or diastolic blood pressure.

LIPID MANAGEMENT IN PATIENTS WITH DIABETES

### LDL GOAL FOR PATIENTS WITH DIABETES WITH AND WITHOUT ASCVD

<table>
<thead>
<tr>
<th>No ASCVD</th>
<th>No LDL treatment goal</th>
<th>Monitoring LDL/lipid panel done to confirm adherence</th>
</tr>
</thead>
<tbody>
<tr>
<td>On statins</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overt ASCVD – includes those with CVD, cerebrovascular disease, and peripheral vascular disease</td>
<td>Treatment goal LDL &lt; 70 mg/dL or at least 50% reduction</td>
<td></td>
</tr>
</tbody>
</table>

**LIPIDS- STATIN TREATMENT FOR PATIENTS WITH DIABETES**

(For details see CCHCS Lipid Care Guide)

**STATINS for DM**

- Statin treatment initiation and monitoring is based on age and risk factors and ASCVD status (see below).

<table>
<thead>
<tr>
<th>AGE</th>
<th>RISK FACTORS PRESENCE OF ASCVD</th>
<th>RECOMMENDED STATIN DOSE INTENSITY*</th>
<th>MONITORING AND TREATMENT GOALS FOR ASCVD</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 40 years</td>
<td>None</td>
<td>None</td>
<td>At initiation of therapy, 4-12 weeks after a change, and annually, or more frequently as clinically indicated (monitoring is primarily done to confirm adherence)</td>
</tr>
<tr>
<td></td>
<td>CVD risk factors**</td>
<td>Moderate</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Overt ASCVD***</td>
<td>High [A]</td>
<td>Lipid panel as indicated to achieve target LDL &lt; 70 mg/dL (2018 ADA, 2013 AHA/ACC) 2017 ACCE recommends goal of &lt;55 mg/dL</td>
</tr>
<tr>
<td>≥ 40 years</td>
<td>None</td>
<td>Moderate</td>
<td>At initiation of therapy, 4-12 weeks after a change, and annually, or more frequently as clinically indicated (monitoring is primarily done to confirm adherence)</td>
</tr>
<tr>
<td></td>
<td>CVD risk factors**</td>
<td>High [A]- patients 40-74 yrs</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>[B]- patients ≥ 75 yrs</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Overt ASCVD***</td>
<td>High [A]- all patients &gt; 40 yrs</td>
<td>Lipid panel as indicated to achieve target LDL &lt; 70 mg/dL (2018 ADA, 2013 AHA/ACC) 2017 ACCE recommends goal of &lt;55 mg/dL</td>
</tr>
</tbody>
</table>

High-intensity statin—Atorvastatin 40 - 80 mg/d
Moderate-intensity statin—Atorvastatin 10 - 20 mg/d or Simvastatin 20-40 mg/d

*In addition to lifestyle therapy.

**CVD risk factors include LDL cholesterol ≥ 100 mg/dL, high blood pressure, smoking, albuminuria, CKD, and overweight and obesity.

***Overt CVD includes those with cardiovascular disease, cerebrovascular disease, and peripheral vascular disease.

**HYPERTRIGLYCERIDEMIA on Statin: Combination Therapy**

- For patients with fasting triglyceride levels ≥ 500 mg/dL, evaluate for secondary causes of hypertriglyceridemia and consider medical therapy to reduce the risk of pancreatitis. [C]
- Statin/fibrate combination has not been shown to improve atherosclerotic cardiovascular disease outcomes and is generally not recommended. [A]
- However, therapy with statin and fenofibrate may be considered for men with:
  - Triglyceride level ≥ 204 mg/dL (2.3 mmol/L) AND
  - High-density lipoprotein (HDL) cholesterol level < 34 mg/dL (0.9 mmol/L) [B]
## CCHCS Care Guide: Type 2 Diabetes

### MONITORING - ADAPTED FROM 2018 ADA RECOMMENDATIONS

#### EXAMS

| Blood pressure | • Check vitals (In Cerner under “Results Review/vitals”) for average BP since last visit  
|                | • If not at goal – Test between visits as clinically indicated while titrating medication  
|                | • At goal – Check each visit  
| Comprehensive foot exam and pulses | • Annually – All patients  
|                                            | • Document in Health Maintenance (Can add a reminder of when next exam is due)  
|                                            | • See page 10 for details on Diabetic Foot Care  
|                                            | • Monofilament exam by care team member (See Attachment 2, page 18)  
| Dental exam | • Annually – Upon patient request  

#### LABS

| A1C | • Not at goal – Check every 90 days (minimum)  
|     | • At goal – Can be every 180 days (minimum) if stable over several months  
| Lipid panel | • At initial visit and if not on medication/statin: check every 5 years (or more often if indicated)  
|            | • If started on lipid medication, check baseline then: 4 – 12 weeks after initiation or change in dose. Annually or more frequently as clinically indicated (monitoring while on a statin is primarily done to confirm adherence unless known ASCVD)  
|            | • Patients with known ASCVD monitoring at least annually for goal of LDL < 70 mg/dL is recommended (2018 ADA)  
| B12* (For patients on Metformin) | • If hemoglobin, hematocrit, red cell indices suggestive or symptoms suggestive of anemia, neuropathy, or deteriorating renal function  
|                                  | • Consider annual level, as anemia is poor indicator of B12 deficiency  
| Urine microalbumin | • Annually – All patients (Spot urinary albumin to creatinine ratio)  
|                    | • Cerner order – “Microalbumin, Random Urine with Creatinine”  
| Serum Creatinine and Glomerular Filtration Rate (GFR) estimate | • Annually in all patients with albuminuria  
|                                    | • See page 9 for GFR Estimation  
| Potassium | • Annually in all patients with albuminuria, on ACE inhibitors (ACEI), Angiotension II receptor blockers (ARBs), or diuretics  
| FSBS | • If ordered, check/document results at each visit – In Cerner under “Results Review/Vitals”  
|      | • Act on results, assess need for continued Fingerstick (FS)  
|      | • Do not order if not acting on results. (FS testing is very burdensome to patients & staff)  
|      | • May not be necessary for Type 2 diabetics who are diet treated or on only oral medications that are not associated with hypoglycemia  
|      | • Oral medication and basal insulin regimens: Once insulin dose stabilizes, may discontinue or monitor FS much less frequently especially if A1C is at goal  
|      | • Note: A fasting or pre-meal FS test is of little value if patient has eaten, defer test  
|      | • Consider a Keep-on-Person (KOP) glucometer if fasting or pre-meal tests are needed but difficult to obtain  
|      | • See Role of Sliding Scale Insulin on page 11  

---

*McCulloch, Metformin in the treatment of adults with type 2 diabetes mellitus, UptoDate Dec 2017; ADA 2018 “B12 as clinically indicated.”*
### VACCINES

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Influenza vaccine</td>
<td>Annually – Offer and encourage for all patients with DM</td>
</tr>
<tr>
<td>Pneumococcal vaccine&lt;sup&gt;1&lt;/sup&gt;</td>
<td>Age ≤ 65 years, one dose of PPSV23 is required</td>
</tr>
<tr>
<td></td>
<td>Age &gt; 65 years, one dose of PCV13 AND a one-time repeat PPSV23 is required</td>
</tr>
<tr>
<td></td>
<td>Keep the PCV13 at least 1 year apart from the last PPSV23 after vaccination</td>
</tr>
<tr>
<td></td>
<td>Keep the final PPSV23 dose at least 1 year from the PCV13 AND 5 years from the first PPSV23</td>
</tr>
</tbody>
</table>

![Diagram showing the timing and intervals for PPSV23 and PCV13 vaccinations.]

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatitis B (HBV) vaccine</td>
<td>Recommended – 2017 CDC:</td>
</tr>
<tr>
<td></td>
<td>► Offer to all patients age 19-59 years and consider HBV vaccine in patients age &gt; 59 years</td>
</tr>
<tr>
<td></td>
<td>► ACP Dec 2017:</td>
</tr>
<tr>
<td></td>
<td>► Vaccinate all unvaccinated adults at risk for infections due to sexual, percutaneous, blood, or mucosal exposure, chronic kidney disease, end stage renal disease, dialysis patients, or HIV infection, or travel to HBV-endemic regions</td>
</tr>
</tbody>
</table>

### SCREENING

<table>
<thead>
<tr>
<th>Screening</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Retinopathy screening</td>
<td>Diabetic Retinopathy:</td>
</tr>
<tr>
<td></td>
<td>► Optimize glycemic, BP, and lipid control to reduce risk or slow progression of retinopathy [A]</td>
</tr>
<tr>
<td></td>
<td>► Eye Exams:</td>
</tr>
<tr>
<td></td>
<td>► Can be performed by an optometrist or ophthalmologist, preferably onsite</td>
</tr>
<tr>
<td></td>
<td>► Initial eye exam: indicated shortly after diagnosis in patients with Type 2 DM</td>
</tr>
<tr>
<td></td>
<td>► Follow-Up eye exam:</td>
</tr>
<tr>
<td></td>
<td>► Annually</td>
</tr>
<tr>
<td></td>
<td>► Patients with normal eye exam and well controlled DM – may consider every 2 years</td>
</tr>
<tr>
<td></td>
<td>► Patient with retinopathy – may need more frequent exams</td>
</tr>
<tr>
<td>Cardiovascular Risk Calculator</td>
<td>Based on:</td>
</tr>
<tr>
<td></td>
<td>- Age</td>
</tr>
<tr>
<td></td>
<td>- Gender</td>
</tr>
<tr>
<td></td>
<td>- Race</td>
</tr>
<tr>
<td></td>
<td>- Total Cholesterol</td>
</tr>
<tr>
<td></td>
<td>- HDL</td>
</tr>
<tr>
<td></td>
<td>- Systolic blood pressure</td>
</tr>
<tr>
<td></td>
<td>- Diastolic blood pressure</td>
</tr>
<tr>
<td></td>
<td>- DM</td>
</tr>
<tr>
<td></td>
<td>- Smoking</td>
</tr>
<tr>
<td></td>
<td>Online ASCVD risk calculator: <a href="http://clincalc.com/cardiology/ASCVD/PooledCohort.aspx">http://clincalc.com/cardiology/ASCVD/PooledCohort.aspx</a></td>
</tr>
<tr>
<td></td>
<td>Calculate once per year; result affects management</td>
</tr>
<tr>
<td>ASA for Primary Prevention</td>
<td>Consider ASA 81mg in patients with increased CV risk</td>
</tr>
<tr>
<td></td>
<td>► If 10-yr CV risk &gt; 10% (calculate using ASCVD Risk calculator), including men &gt; 50 years of age or women &gt; 60 who have at least one additional major risk factor for CVD other than DM (e.g., dyslipidemia, hypertension [HTN], smoking, albuminuria, family history of premature CVD)</td>
</tr>
<tr>
<td></td>
<td>► Clopidogrel 75mg/day should be used for those with ASA allergy</td>
</tr>
</tbody>
</table>

---

CCHCS Care Guide: Type 2 Diabetes

August 2018

SUMMARY

DIABETIC NEPHROPATHY MONITORING

MICROALBUMINURIA – False Positives occur ensuring 2 tests over 3 – 6 MONTHS

- Measure urine albumin excretion annually starting at diagnosis.
- Order “Microalbumin, Random Urine with Creatinine.” (Order includes microalbumin/creatinine ratio).
- Normal albuminuria: < 30 mg/day.
- Microalbuminuria: 30 to < 300 mg/day. Start treatment, reduces progression.
- Macroalbuminuria: ≥ 300 mg/day.

TREATMENT OF ALBUMINURIA

- DM with normal albumin and normal BP No treatment indicated. Normotensive primary prevention is NOT recommended.
- DM with hypertension and normal albumin ACEI or ARB\(^1\) (discontinue if serum Cr increases > 30% over baseline on initiation)
- DM with albuminuria (≥ 30 mg/day) and normal BP ACEI or ARB\(^1\) (discontinue if serum Cr increases > 30% over baseline on initiation)

Treatments to reduce albuminuria should not reduce GFR. ACEI or ARB should be discontinued when serum creatinine concentration increases > 30% above the baseline value.**


GLOMERULAR FILTRATION RATE (GFR) ESTIMATION

- eGFR done automatically with Cerner order of: “Creatinine, Creatinine Clearance, BUN/Creatinine ratio, Basic Metabolic Panel or Comprehensive Metabolic Panel” (but NOT with Creatinine – 24 hour urine).
- Complications of kidney disease correlate with eGFR (see table on Stages of CKD below).

STAGES OF CKD\(^2\)

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
<th>GFR (ml/min/1.73m(^2))</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Kidney damage* with normal or increased GFR</td>
<td>≥ 90</td>
</tr>
<tr>
<td>2</td>
<td>Kidney damage* with normal or decreased GFR</td>
<td>60-89</td>
</tr>
<tr>
<td>3</td>
<td>Moderately decreased GFR</td>
<td>30-59</td>
</tr>
<tr>
<td>4</td>
<td>Severely decreased GFR</td>
<td>15-29</td>
</tr>
<tr>
<td>5</td>
<td>Kidney failure</td>
<td>&lt; 15 or dialysis</td>
</tr>
</tbody>
</table>

*Kidney damage is defined as abnormalities on pathological, urine, blood, or imaging tests.

MANAGEMENT OF CKD IN DM\(^1\)

<table>
<thead>
<tr>
<th>GFR (ml/min/1.73m(^2))</th>
<th>Recommended Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>All diabetic patients</td>
<td>Yearly measurement of creatinine, urinary albumin excretion, potassium</td>
</tr>
<tr>
<td>45-60</td>
<td>Referral to a nephrologist recommended for CKD stage 3 or higher</td>
</tr>
<tr>
<td>30-44</td>
<td>Monitor estimated GFR (eGFR) every 3 months</td>
</tr>
<tr>
<td></td>
<td>Monitor electrolytes, bicarbonate, calcium, phosphorus, parathyroid hormone, hemoglobin, albumin, weight every 3-6 months</td>
</tr>
<tr>
<td></td>
<td>Consider the need for adjustment of medication doses due to reduction in renal function</td>
</tr>
<tr>
<td>&lt; 30</td>
<td>Referral to a nephrologist</td>
</tr>
</tbody>
</table>

\(^1\)National Kidney Foundation. KDOQI Clinical Practice Guideline for diabetes and CKD: 2012 update.

### SUGGESTED FOOT EXAM ELEMENTS

| **History** | • High risk feet conditions from above  
• Neuropathic symptoms: pain, numbness, tingling, prickling, pins and needles sensation  
• Vascular symptoms: claudication  
• Impaired vision  
• Tobacco use  
• Foot care practices, shoe wear |
| **Inspection** | • Skin: focal lesions e.g., calluses, maceration, ulcers, dry skin, tinea pedis  
• Nails: onychomycotic or dystrophic nails  
• Deformities: hammer toe, bunion, pes planus or pes cavus |
| **Vascular Exam** | • Peripheral arterial disease (PAD) suggested by absence of dorsalis pedis and posterior tibial pulses, dependent rubor, and capillary filling time of > 3 seconds  
• Consider Ankle Brachial Index (ABI) in any patient with signs and symptoms of PAD, especially in diabetics > 50 years |
| **Neurologic Sensory Exam** | Test for LOPS using:  
• **10-g monofilament test** (See Attachment 2, page 18)  
• **And at least one of the following:**  
  ▶ Vibration using 128 Hz tuning fork tested at tip of great toe bilaterally  
  ▶ Pinprick sensation, using a disposable pin applied just proximal to the toenail on dorsal surface of hallux using just enough pressure to deform skin. Inability to perceive pinprick over either hallux is an abnormal test result.  
  ▶ Ankle reflexes  
One or more abnormal results suggests LOPS  
At least two normal tests (and no abnormal) rules out LOPS |

### CONSULTATION, DIABETIC SHOES, AND ORTHOTICS

- Consider consultation and/or authorization of diabetic shoes and/or orthotics for diabetic patients with high risk feet as defined above.

- Also consider consultation with Podiatry for patients with onychomycosis causing deformity of the nail or nail bed.

- Patients with diabetes and a diagnosis of diabetic sensory neuropathy with LOPS should be referred to podiatry for what might ordinarily be considered routine primary or personal care. The following procedures may pose a hazard when performed by a non-trained professional:  
  - Cutting or removing corns and calluses  
  - Trimming, cutting, clipping or debriding nails
## NPH to insulin glargine
- NPH once daily: Convert unit-for-unit (1:1) to glargine and give once daily.
- NPH twice daily: Glargine dose should be 80% of total NPH dose and given once daily.

## Insulin glargine to NPH
- Convert unit-for-unit from glargine to NPH and give twice daily (e.g., 1/2 AM and 1/2 PM or 2/3 AM and 1/3 PM).

## ROLE OF SLIDING SCALE INSULIN (SSI)

### National Guidelines - SSI:
- 2009: ADA - DO NOT USE for outpatients and stop using long term SSI in DM.
- 2008: American Medical Directors Association recommends to AVOID.
- 2012: American Geriatrics Society - Beers Criteria Update Expert Panel recommends to AVOID.
- 2016: FBOP - SSI NOT a recommended strategy for long-term management.

### Reasons not to use SSI:
- Nonphysiologic – Reactive to high blood sugar that already occurred and doesn’t prevent elevation in future and leads to rollercoaster effect.  
  (Nalysnyk, Glycaemic variability and complications in patients w DM, 2010)
- Requires patient to become hyperglycemic before treatment given as most SSI start at 180 mg/dL and provider alerts often > 300 mg/dL.  
  (Konrad, Glycemic control in hospitalized patients not in ICU, beyond SSI, Am Family Physician 2010)
- Greater patient discomfort.
- Increased nursing time due to increased monitoring.
- Increased nursing time due to increased number of injections administered.
- Typical notifications (e.g., < 60 and > 400 mg/dL) may result in periods of hypoglycemia or hyperglycemia without adjustments in therapy.
- SSI lends itself to a failure of adjustment: A large medical center retrospective study: 84% of SSI patients with hyperglycemia, only 18% had dose adjustments.  
  (Golightly, Management of DM in hospitalized patients, Pharmacotherapy 2006)

### Appropriate use:
- Use short term SSI when titrating insulin, THEN STOP.
- May use temporarily when patient is acutely ill, or nothing by mouth for any reason.

### INPATIENT
- 2010 American Family Physician Traditional SSI should be abandoned as the sole means of controlling blood sugar in hospitalized patients.
- 2016: ADA - sole use of sliding scale insulin in the inpatient hospital setting is strongly discouraged.

### Patients treated with SSI alone had hyperglycemia > 300 mg/dL three times more often than other regimens.  
(Queale, Glycemic control and SSI use in medical inpatients with DM, 1997)

### Basal insulin shown to provide superior glycemic control with less risk of hypoglycemia.  
(Maynard, improved inpatient use of basal insulin 2009)

### Recommended to use basal and basal/prandial insulin as the foundation.  
Correction Factor insulin is ordered to be given prospectively with prandial insulin if needed and if used frequently, is added to the basal/prandial at previous meal.  
Limited use of SSI is occasionally needed on a temporary basis in extremely sick patients.
### Antihyperglycemic Medication Characteristics

<table>
<thead>
<tr>
<th>Medication Class</th>
<th>CV Effects</th>
<th>Cost</th>
<th>Advantages</th>
<th>Disadvantages</th>
<th>Additional Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Metformin</strong></td>
<td>ASCVD: Potential Benefit, CHF: Neutral</td>
<td>Low</td>
<td>Extensive experience, Rare hypoglycemia</td>
<td>Lactic acidosis risk (rare)</td>
<td>Gastrointestinal side effects common (diarrhea, nausea), Potential for B12 deficiency</td>
</tr>
<tr>
<td><strong>Sulfonylureas (2nd Generation)</strong></td>
<td>ASCVD: Neutral, CHF: Neutral</td>
<td>Low</td>
<td>Extensive experience, Microvascular risk</td>
<td>Hypoglycemia</td>
<td>FDA Special Warning on increased risk of cardiovascular mortality based on studies of an older sulfonylurea (tolbutamide)</td>
</tr>
<tr>
<td><em>Glitazones</em></td>
<td>ASCVD: Potential Benefit: pioglitazone</td>
<td>↑ Risk</td>
<td>Rare hypoglycemia, Durability</td>
<td>Edema/heart failure, Bone fractures</td>
<td>FDA Black Box: Congestive heart failure, Fluid retention (edema; heart failure), Benefit in Nonalcoholic Fatty Liver Disease, Risk of bone fractures, Bladder cancer (pioglitazone)</td>
</tr>
<tr>
<td><strong>Thiazolidinediones</strong></td>
<td>ASCVD: Neutral, CHF: Neutral</td>
<td>Low</td>
<td>Nearly universal response, Microvascular risk</td>
<td>Hypoglycemia, Training requirements, Patient and provider reluctance, Injectable (except inhaled insulin), Pulmonary toxicity (inhaled insulin)</td>
<td>Injection site reactions, Higher risk of hypoglycemia with human insulin (NPH or premixed formulations) vs. analogs</td>
</tr>
<tr>
<td><strong>Insulin</strong></td>
<td>ASCVD: Human Insulin, CHF: Neutral</td>
<td>High</td>
<td>Nearly universal response</td>
<td>Hypoglycemia, Training requirements, Patient and provider reluctance, Injectable (except inhaled insulin), Pulmonary toxicity (inhaled insulin)</td>
<td>Injection site reactions, Higher risk of hypoglycemia with human insulin (NPH or premixed formulations) vs. analogs</td>
</tr>
<tr>
<td><strong>Analog Analogs</strong></td>
<td>ASCVD: Neutral, CHF: Neutral</td>
<td>Low</td>
<td>Nearly universal response</td>
<td>Hypoglycemia, Training requirements, Patient and provider reluctance, Injectable (except inhaled insulin), Pulmonary toxicity (inhaled insulin)</td>
<td>Injection site reactions, Higher risk of hypoglycemia with human insulin (NPH or premixed formulations) vs. analogs</td>
</tr>
<tr>
<td><strong>GLP-1 Receptor agonists</strong></td>
<td>ASCVD: Benefit: liraglutide+, CHF: Neutral</td>
<td>High</td>
<td>Rare hypoglycemia, Postprandial glucose excursions, Some cardiovascular risk factors, Heart rate, C-cell hyperplasia/medullary thyroid tumors in animals</td>
<td>Heart failure hospitalizations, Potential for B12 deficiency</td>
<td>FDA Black Box: Risk of thyroid C-cell tumors (liraglutide, aliglutide, dulaglutide, exenatide, exenatide ER)</td>
</tr>
<tr>
<td><em>Glutides</em></td>
<td>ASCVD: Potential Risk: saxagliptin, alogliptin, CHF: Neutral</td>
<td>High</td>
<td>Rare hypoglycemia, Well tolerated</td>
<td>Angioedema/urticaria and other immune-mediated dermatological effects</td>
<td>Potential risk of acute pancreatitis, Joint pain</td>
</tr>
<tr>
<td><strong>DPP-4 Inhibitors</strong></td>
<td>ASCVD: Neutral, CHF: Potential Risk: saxagliptin, alogliptin</td>
<td>High</td>
<td>Rare hypoglycemia, Blood pressure</td>
<td>Angioedema/urticaria and other immune-mediated dermatological effects</td>
<td>Potential risk of acute pancreatitis, Joint pain</td>
</tr>
<tr>
<td><em>Gliptins</em></td>
<td>ASCVD: Benefit: canagliflozin, empagliflozin+, CHF: Benefit: canagliflozin, empagliflozin</td>
<td>High</td>
<td>Rare hypoglycemia, Blood pressure, Polyuria, Dizziness</td>
<td>Polycythemia, Creatinine (transient)</td>
<td>FDA Black Box: Risk of amputation (canagliflozin), Risk of bone fractures (canagliflozin), DKA risk (all agents, rare in T2DM), Genitourinary infections, Risk of volume depletion, hypotension, LDL cholesterol</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Medication Class</th>
<th>CV Effects</th>
<th>Cost</th>
<th>Advantages</th>
<th>Disadvantages</th>
<th>Additional Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SGLT2 Inhibitors</strong></td>
<td>ASCVD: Benefit: canagliflozin, empagliflozin+</td>
<td>High</td>
<td>Rare hypoglycemia, Blood pressure</td>
<td>Polycythemia, Creatinine (transient)</td>
<td>FDA Black Box: Risk of amputation (canagliflozin), Risk of bone fractures (canagliflozin), DKA risk (all agents, rare in T2DM), Genitourinary infections, Risk of volume depletion, hypotension, LDL cholesterol</td>
</tr>
</tbody>
</table>

*FDA approved for CVD benefit. CVD cardiovascular disease; DKA, diabetic ketoacidosis; DKD diabetic kidney disease; NASH, nonalcoholic steatohepatitis; RAs, receptor agonists; SQ subcutaneous; T2DM, type 2 diabetes.

CVD cardiovascular disease; DKA, diabetic ketoacidosis; DKD diabetic kidney disease; NASH, nonalcoholic steatohepatitis; RAs, receptor agonists; SQ subcutaneous; T2DM, type 2 diabetes.

Adapted from: Table 8.1—Drug specific and patient factors to consider when selecting antihyperglycemic treatment in adults with type 2 diabetes from ADA 2018, page S77 and Table 8.2—Pharmacology of available glucose-lowering agents in the U.S. for the treatment of type 2 diabetes from ADA 2018, page S79-S80.

### MANAGEMENT OF HYPOGLYCEMIA IN CCHCS

#### PREVENTION
- Patients who are prone to hypoglycemia should have access to glucose tablets, glucose gel, or a diabetic snack.
- Staff members should also have ready access to glucose tablets or the equivalent.
- Patients receiving insulin or oral antihyperglycemic agents may develop hypoglycemia during illness, with greatly increased activity (exercise) level, or decreased food intake. Profound hypoglycemia may develop when meals are delayed or missed.
- Ask about hypoglycemic episodes at each visit.
- Custody staff shall ensure that patients receiving insulin have access to their next scheduled meal within 30 minutes of insulin injections.
- Elderly patients should be monitored for signs of hypoglycemia.
- **Patients must be counseled:**
  - Regarding the importance of a consistent diet and activity level.
  - To report for insulin injection prior to eating (fasting) to ensure meaningful FS glucose results.
  - To report for meals promptly after receiving insulin injections.
  - To discuss with his/her provider possible insulin or oral hypoglycemic dosage adjustments during illness.
  - To tell the RN if the FS is in fact, post prandial so it can be documented with the FSBS.

#### TREATMENT

<table>
<thead>
<tr>
<th>Classification of Hypoglycemia</th>
<th>Description</th>
<th>Treatment</th>
</tr>
</thead>
</table>
| **Alert Value ≤ 70 mg/dL**    | Conscious with or without symptoms | **Acute phase:**
But any form of carbohydrate that contains glucose can be used:
- Austin Peanut butter/cheese and crackers pack = 16 carbs and 3g of sugar.
- Keebler Graham cracker pack = 11 g carbs and 3g sugars.
- Clinic and KOP sugar tablets are 4 g of sugar each.
- There is also a 40% dextrose gel which have 22 grams of sugar each.
Recheck in 15 minutes, if still <70 mg/dL, repeat above.
Follow with high sugar content snack with low protein and fat*.
**Once normoglycemic (BS >80 mg/dl)** – eat meal or snack.
Consider bedtime snack if at continued risk. |
| **Clinically Significant < 54 mg/dL** | Serious and clinically important | Same as above with vigilance for progression to severe. |
| **Severe** | Associated with immediate mortality and 5-year mortality and increases risk for development of dementia | **Glucagon 1 mg IM, IV or subQ** (Crash carts carry a 1 mg syringe kit).
If fails, use IV Dextrose.
**Repeat every 15 minutes** as needed.
Administer IV Dextrose as soon as it is available (Crash carts carry bags of Dextrose 50% solution)
Prolonged monitoring may be required if on long-acting insulin or insulin secretagogues.
If unexplained or recurrent severe, on long acting insulin or on insulin with poor oral intake: Admission to a medical unit for observation and stabilization may be indicated.
ADA advises to increase glycemic targets for at least several weeks as it has been demonstrated to improve counter-regulation and hypoglycemic awareness.* |

---

*Fat may retard and then prolong the acute glycemic response. In type II DM, protein may increase insulin response without increasing plasma glucose concentrations.
Adapted from 2018 ADA Vol 41, Supplement 1, Glycemic Targets, pg S61.
**Summary**

**ORAL DM MEDICATIONS**

<table>
<thead>
<tr>
<th>DRUG CLASS / MEDICATION</th>
<th>DOING</th>
<th>ADVERSE EFFECTS / INTERACTIONS*</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metformin (Glucophage®)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Tablet (IR): 500 mg, 850 mg, 1000 mg tabs | Initial dose: 500 mg twice daily or 850 mg once daily with meals  
Titration: After 5-7 days if no GI side effects, increase dose by 500 mg weekly or 850 mg twice daily every other week. (Titrate dose slowly to minimize Gl effects)  
Max dose: Max effective dose may be 1000 mg twice daily, often max effect seen at 850 mg twice daily. Modestly greater efficacy seen with doses up to 2500 mg/day  
Max dose: 2550 mg/day (Doses > 2000 mg/day better tolerated if given three times daily with meals)  
Hepatic impairment: Avoid  
Renal impairment: Contraindicated in eGFR < 30 mL/min. eGFR 31-44 mL/min – Use not recommended. If eGFR < 45 mL/min after initiation - assess benefits and risks of continuing treatment; if eGFR falls < 30 – discontinue | Black Box Warning: Lactic acidosis, rare but potentially serious. Risk increases with degree of renal impairment, CHF or impaired liver function. Discontinue during acute illness or during hunger strikes where dehydration may occur.  
Adverse events: Nausea, diarrhea, cramping, flatulence  
May cause vitamin B12 deficiency with anemia and neuropathy which may be confused with diabetic neuropathy  
Modest weight loss may occur  
Drug interactions: Iodinated contrast agents | Expected A1C reduction: 1.0 - 2.0%  
Contraindications: Patients with factors predisposing to lactic acidosis: Renal insufficiency with eGFR < 30 mL/min  
Temporarily discontinue metformin prior to or at time of IV iodinated contrast administration and withhold for 48 hours thereafter. Restart upon confirmation of normal renal function  
Suspend therapy for surgical procedures and resume with confirmation of normal renal function  
Pregnancy: Category B  
Lactation: Enters breast milk, not recommended |
| Glipizide (Glucotrol®)  |       |                                  |          |
| Tablet (IR): 5 mg, 10 mg | Initial dose: 5 mg once daily;  
2.5 mg once daily in elderly  
Titration: Increase dose by 2.5 mg or 5 mg every 1-2 weeks  
Max dose: 40 mg/day  
(Doses >15 mg/day should be divided into 2 doses)  
Hepatic impairment: Initial dose 2.5 mg/day  
DO NOT USE GLYBURIDE | Adverse events: Hypoglycemia, weight gain, dizziness, nausea, asthenia  
Increased risk of hypoglycemia when sulfonfonylurea used with nonbasal insulin  
Stop when on basal with prandial insulin regimens | Expected A1C reduction: 1.0 - 2.0%  
Glyburide is no longer recommended due to hypoglycemic risk  
Best given before a meal, preferably breakfast (if once daily dosing)  
Possible cross reaction in those allergic to sulfonylamides  
Pregnancy: Category C  
Lactation: Unknown effect, not recommended |
| Pioglitazone (Actos®)  |       |                                  |          |
| Tablet: 15 mg, 30 mg, 45 mg | Initial dose: 15-30 mg once daily  
Titration: Increase dose by 15 mg increments  
Max dose: 45 mg/day  
Concomitant CYP2C8 inhibitors (e.g., gemfibrozil) or CHF (NYHA class I or II): Max 15 mg/day  
Hepatic impairment: Moderate or severe: Avoid | Black Box Warning: May cause or exacerbate heart failure. Closely monitor for signs and symptoms of heart failure, especially after initiation or dose increase. If heart failure occurs treat accordingly and consider dose reduction or discontinuation.  
Adverse effects: Weight gain, edema, CHF, possible hepatic injury; possible increased risk  
Drug interactions: Strong CYP2C8 inhibitors (e.g., gemfibrozil); CYP2C8 inducers (e.g., rifampin) | Expected A1C reduction: 0.5 - 1.4%  
Contraindications: Symptomatic CHF; CHF NYHA Class III or IV  
Caution: Combination use with insulin in patients with heart failure, and CHF NYHA Class I and II  
Monitor LFTs, avoid if ALT > 2.5 times normal before starting therapy, discontinue if ALT > 3 times normal during therapy  
If used with insulin, reduce insulin dose by 10-25% once FBG <120 mg/dl  
Reduce dose of sulfonfonylurea when used with T2Ds to minimize hypoglycemia risk  
Pregnancy: Category C  
Lactation: Unknown effect, not recommended |

The cost scale $-$ represents the relative cost of acquisition of medication only. Frequency and complexity of medication administration (institution workload, effect on adherence) should be considered when determining overall cost-effectiveness of treatment.

Bold = Formulary  
*See prescribing information for complete description of adverse effects and drug interactions.*

14
**ORAL DM MEDICATIONS CONTINUED**

<table>
<thead>
<tr>
<th>MEDICATION</th>
<th>DOSing</th>
<th>ADVERSE EFFECTS / INTERACTIONS*</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Empagliflozin (Jardiance®)</td>
<td>Initial dose: 10 mg PO once daily, taken in the morning, without or without food.</td>
<td>Adverse effects: Intravascular volume contraction. Symptomatic hypotension can occur after initiating emagliflozin.</td>
<td>Expected A1C reduction: 0.5% - 0.7%</td>
</tr>
<tr>
<td>10 mg and 25 mg oral tablets</td>
<td>Titration: The dose can be increased to 25 mg PO once daily in those who require additional glycemic control. Maximum dosage: 25 mg/day. Renal Impairment: eGFR ≥ 45 mL/min: No dosage adjustment needed eGFR &lt; 45 mL/min: Do not initiate emagliflozin in these patients. In patients currently taking the drug, emagliflozin should be discontinued when eGFR is persistently &lt; 45 mL/min/1.73 m².</td>
<td>Dehydration, hypotension, urinary frequency, urinary tract infections, including urosepsis and pyelophritis, balanitis, vaginitis, endocrinopathies, hypoglycemia, hypercholesterolemia, polydypsia. Patients with pre-existing hypercholesterolemia. Monitor LDL-C. Dose-related increases in LDL. Geriatric patients ≥ 75 years old experienced an ↑ incidence of S/E Drug Interactions: Major: chloroquines; Moderate: beta blockers, amiodipine, thiazides, ACEI and ARBs, estrogens, progestins and androgens, HIV &quot;avir&quot; medications, atypical antipsychotics, calcium channel blockers, lithium, corticosteroids, loop diuretics.</td>
<td></td>
</tr>
<tr>
<td>Nonformulary preferred</td>
<td></td>
<td>Contraindications: Patients with history of serious hypersensitivity reaction to emagliflozin. Patients with severe renal impairment (eGFR less than 30 mL/min), ESRD/dialysis. Cautions: Serious hypersensitivity reactions or anaphylaxis, including angioedema, have been reported in patients receiving emagliflozin.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Patients at risk of acute kidney injury, include those with dehydration or hypovolemia, particularly in patients with impaired renal function (i.e., eGFR 45 to 60 mL/min), the elderly, patients receiving diuretics, or patients with low systolic blood pressure.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Use cautiously in patients with a history of genital fungal infection, including vaginitis or balanitis, and in uncircumcised males.</td>
<td></td>
</tr>
</tbody>
</table>

**Dipeptidyl Peptidase-4 (DPP-4) Inhibitors**

<table>
<thead>
<tr>
<th>INJECTABLE MEDICATIONS - (INJECTABLE INSULIN MEDICATIONS)</th>
<th>INSULIN CLASS</th>
<th>SPECIFIC INSULIN</th>
<th>ONSET</th>
<th>PEAK</th>
<th>DURATION</th>
<th>COST</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sitagliptin (Januvia®) Tablets: 25 mg, 50mg, 100 mg</td>
<td>Short-acting*</td>
<td>Regular–Humulin R®</td>
<td>30-60 minutes</td>
<td>2 to 4 hours</td>
<td>5 to 10 hours</td>
<td>$$</td>
</tr>
<tr>
<td>Nonformulary preferred</td>
<td>Intermediate-acting</td>
<td>NPH–Humulin N®</td>
<td>1 to 2 hours</td>
<td>4 to 8 hours</td>
<td>10 to 20 hours</td>
<td>$$</td>
</tr>
<tr>
<td></td>
<td>Premixed</td>
<td>NPH/regular–Humulin 70/30®</td>
<td>30 minutes</td>
<td>Dual peak</td>
<td>Up to 24 hours</td>
<td>$$</td>
</tr>
<tr>
<td></td>
<td>Long-acting (basal)</td>
<td>Gliptine–Lantus® (Not to be mixed with other insulins)</td>
<td>1 to 2 hours</td>
<td>Relatively flat</td>
<td>20 to 24 hours</td>
<td>$$$</td>
</tr>
<tr>
<td>Rapid or Ultra rapid-acting*</td>
<td>Lispro (Humalog)</td>
<td>15-30 minutes</td>
<td>30-90 min</td>
<td>3-5 hours</td>
<td>$$$</td>
<td></td>
</tr>
<tr>
<td>*DO NOT USE - NOT INDICATED IN CORRECTIONAL SETTING PER CCHCS POLICY. FBOP in general does not use rapid-acting</td>
<td>Aspart (Novolog)</td>
<td>10-20 min</td>
<td>40-50 min</td>
<td>3-5 hours</td>
<td>$$$</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Glulisine (Apidra)</td>
<td>20-30 min</td>
<td>30-90 min</td>
<td>1 to 1.5 hours</td>
<td>$$$</td>
<td></td>
</tr>
</tbody>
</table>

*Every effort should be made to administer rapid-acting insulin before meals. However in rare circumstances when patient movement may be disrupted and risk of hypoglycemia is high, rapid acting insulin may be administered shortly after meals.*

**The cost scale $-$$$$ represents the relative cost of acquisition of medication only. Frequency and complexity of medication administration (institution workload, effect on adherence) should be considered when determining overall cost-effectiveness of treatment.**

**Bold = Formulary**

*See prescribing information for complete description of adverse effects and drug interactions.*
<table>
<thead>
<tr>
<th>Medication</th>
<th>Dosing</th>
<th>Adverse Effects / Interactions*</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liraglutide (Victoza&lt;sup&gt;®&lt;/sup&gt;)</td>
<td>Injection soln: 1 mL, 6 mg</td>
<td>Black Box Warning: Liraglutide has been shown to cause dose-dependent and treatment duration-dependent malignant thyroid C-cell tumors at clinically relevant exposures in animal studies at 8 times normal dose. Relevance in humans is not known.</td>
<td></td>
</tr>
<tr>
<td>Nonformulary preferred</td>
<td></td>
<td>Adverse effects: GI: Slows gastric emptying with resultant nausea, vomiting and diarrhea. Anorexia, dyspepsia, headache, flatulence, constipation, hypoglycemia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Initial dose: Administer once daily at any time of day, independently of meals. Initially, 0.6 mg subcutaneously once daily for 1 week. The 0.6 mg dose is a starting dose intended to reduce gastrointestinal (GI) symptoms during initial titration and is not effective for glycemic control. Administer by subcutaneous injection only. Do not administer by intravenous or intramuscular injection. Titration: After 1 week, increase the dose to 1.2 mg subcutaneously once daily. If acceptable glycemic control not achieved, the dose can be increased to 1.8 mg subcutaneously once daily. If a dose is missed, resume the once daily regimen as prescribed with the next scheduled dose. If more than 3 days have elapsed since the last dose, reinitiate at 0.6 mg in order to alleviate any GI symptoms associated with re-initiation of treatment. The dose should then be re-titrated appropriately. Max dose: 1.8 mg/day SC</td>
<td>Hypoglycemia should be monitored by the patient and clinician when liraglutide treatment is initiated and continued.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fatigue, infections, dizziness, antibody formation, injection site reactions</td>
<td>Hypoglycemia was increased when liraglutide was used in combination with a sulfonylurea. Consider lowering sulfonylurea or discontinuing when starting liraglutide. Liraglutide has not been evaluated for use in combination with prandial insulin.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Severe but less common: Cholecystitis, pancreatitis, AV Block, suicidal ideation, angioedema, anaphylactoid reactions, bronchospasm, palpitations</td>
<td>Expected A1C reduction: 0.5-1.0%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Drug Interactions: Major: hydroxyquinalone and chloroquine</td>
<td>Contraindications: Patients with a personal or family history of certain types of thyroid cancer, specifically medullary thyroid carcinoma (MTC), or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2).</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Moderate: Salicylates, Beta Blockers Acetaminophen, ASA, caffeine, Phenyltoloxamine, lithium Acetazolamide, Alikiren Valsartan, Anliodipine, HCTZ,</td>
<td>Patients with a history of serious hypersensitivity reaction to liraglutide</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Androgens, progestins and estrogens. Metoclopramide, ACE I and ARBs, omeprazole, oxycodone, fibric acid derivatives, fluoxetine, Insulins, Sulfanamides, Calcium channel blockers, Dirunavir, cyclosporins, Clonidine, Ciprofloxin</td>
<td>Caution: Patients with a history of angioedema to other GLP-1 receptor agonists. Serious hypersensitivity reactions have been reported during post marketing use with liraglutide, such as anaphylaxis or angioedema. Liraglutide should not be used in patients with Type 1 DM or for the treatment of diabetic ketoacidosis. Use caution in patients with gastroparesis. There is limited information available on the use of liraglutide in patients with renal impairment. There is limited information available on the use of liraglutide in patients with hepatic disease. Patients with risk factors for pancreatitis (cholelithiasis, GB disease, alcoholism, prior history). Pregnancy: Category C Lactation: Unknown effect, use caution. Caution: Patients with depression and avoid use in patients with a history of suicide attempts or active suicidal ideation. Monitor patients receiving liraglutide for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.</td>
</tr>
</tbody>
</table>

The cost scale $$$$$ represents the relative cost of acquisition of medication only. Frequency and complexity of medication administration (institution workload, effect on adherence) should be considered when determining overall cost-effectiveness of treatment.

**Bold = Formulary**

*See prescribing information for complete description of adverse effects and drug interactions.
### ATTACHMENT 1

#### SETTING TARGET FOR GLYCEMIC CONTROL

<table>
<thead>
<tr>
<th>PATIENT/DISEASE FEATURES</th>
<th>More stringent</th>
<th>A1C 7%</th>
<th>Less stringent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risks potentially associated with hypoglycemia and other drug adverse effects</td>
<td>Low</td>
<td>High</td>
<td></td>
</tr>
<tr>
<td>Disease duration</td>
<td>Newly diagnosed</td>
<td>Long-standing</td>
<td></td>
</tr>
<tr>
<td>Life expectancy</td>
<td>Long</td>
<td>Short</td>
<td></td>
</tr>
<tr>
<td>Important comorbidities</td>
<td>Absent</td>
<td>Few / Mild</td>
<td>Severe</td>
</tr>
<tr>
<td>Established vascular complications</td>
<td>Absent</td>
<td>Few / Mild</td>
<td>Severe</td>
</tr>
<tr>
<td>Patient attitude and expected treatment efforts</td>
<td>Highly motivated, adherent, excellent self-care capacities</td>
<td>Less motivated, non adherent, poor self-care capacities</td>
<td></td>
</tr>
<tr>
<td>Resources and support system</td>
<td>Readily available</td>
<td>Limited</td>
<td></td>
</tr>
</tbody>
</table>

- This "scale" is not designed to be applied rigidly but to be used as a broad construct to help guide clinical decisions.
- Those with long duration of diabetes, known history of severe hypoglycemia, advanced atherosclerosis, and advanced age/frailty may benefit from less aggressive targets.
- Providers should be vigilant in preventing severe hypoglycemia in patients with advanced disease and should not aggressively attempt to achieve near-normal A1C levels in patients in whom such targets cannot be safely and reasonably achieved.

---

**ATTACHMENT 2**

**MONOFILAMENT TESTING\(^1\)**

(SINGLE USE DISPOSABLE MONOFILAMENTS ARE RECOMMENDED)

<table>
<thead>
<tr>
<th>1.</th>
<th>Place patient in supine or sitting position with shoe and socks removed.</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.</td>
<td>Touch the disposable monofilament to patient’s skin on his/her arm or hand to demonstrate what the touch feels like.</td>
</tr>
<tr>
<td>3.</td>
<td>Instruct patient to respond “yes” each time he/she feels the pressure of the monofilament on his/her foot during the exam.</td>
</tr>
<tr>
<td>4.</td>
<td>Instruct patient to close his/her eyes with toes pointing straight up during the exam.</td>
</tr>
<tr>
<td>5.</td>
<td>Hold the monofilament perpendicular to the patient’s foot (see top panel of diagram below).</td>
</tr>
<tr>
<td>6.</td>
<td>Press it against the foot, increasing the pressure until the monofilament bends into a C-shape. Do not apply over ulcer, callus, scar, or necrotic tissue. Do not slide monofilament over the skin.</td>
</tr>
<tr>
<td>7.</td>
<td>Inform the patient you will test each location twice, one touch will be real and one will not. Press the filament to the skin such that it buckles (and hold in place for about 1 second) at one of two times you test each site as you say &quot;time one&quot; or &quot;time two.&quot; Have patients identify at which time they were touched.</td>
</tr>
<tr>
<td>8.</td>
<td>It is recommended to test at least 4 sites on each foot (see lower panel of diagram below: 1st, 3rd, and 5th metatarsal heads and plantar surface of distal hallux, other spots are optional).</td>
</tr>
<tr>
<td>9.</td>
<td>Randomize the sequence of applying the filament or not throughout the examination.</td>
</tr>
<tr>
<td>10.</td>
<td>Record response on foot screening form with “+” for yes it was felt and “-” for no. The patient should recognize the perception of pressure and identify the correct site.</td>
</tr>
<tr>
<td>11.</td>
<td>When the monofilament is not felt, protective sensation is absent, placing the person at high risk for development of a neuropathic ulcer.</td>
</tr>
</tbody>
</table>

---

DETECTION AND DIAGNOSIS OF GESTATIONAL DIABETES MELLITUS (GDM)¹

Patients should be screened in the first trimester who have a BMI ≥ 25 kg/m² and any of the following risk factors:

- Physical inactivity
- First degree relative with DM
- High-risk race/ethnicity (African American, Latino, Native American, Asian American, Pacific Islander)
- Hypertension (BP > 140/90 mmHg or on treatment for Hypertension)
- Hypercholesterolemia
- A1C ≥ 5.5% (36.6 mmol/mol, IGT, IFG on previous testing)
- Delivered a baby weighing > 9 pounds (4.1 kg) or previously diagnosed with GDM
- Clinical conditions associated with insulin resistance (e.g., Acanthosis nigricans, Polycystic Ovarian Syndrome)
- History of CVD
- Smoking

All pregnant patients who were not screened in the first trimester, should be tested for GDM at 24-28 weeks of gestation. [A]

**Screening and Diagnosis:**
1. Perform an 8 hour fasting 75-g OGTT at 24-28 weeks of gestation in women not previously diagnosed with overt DM.

Diagnostic for GDM if:
- Fasting: 92 mg/dl (a fasting glucose of > 126 is diagnostic of overt DM [Pre-gestational diabetes])
- 1 h: 180 mg/dl
- 2 h: 153 mg/dl

2. Two-Step non-fasting 50 g Glucose Load Testing
- 1 h: if it is ≥ 140 mg/dl, proceed to a fasting 100-g OGTT
- Diagnostic for GDM if (at least two of the following four):

<table>
<thead>
<tr>
<th>Thresholds</th>
<th>Carpenter/Coustan*</th>
<th>NDDG**</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fasting</td>
<td>95 mg/dl</td>
<td>105 mg/dl</td>
</tr>
<tr>
<td>1 hour</td>
<td>180 mg/dl</td>
<td>190 mg/dl</td>
</tr>
<tr>
<td>2 hour</td>
<td>155 mg/dl</td>
<td>165 mg/dl</td>
</tr>
<tr>
<td>3 hour</td>
<td>140 mg/dl</td>
<td>145 mg/dl</td>
</tr>
</tbody>
</table>

Thresholds vary depending on the organization/authors. The most commonly cited (per Up to Date) are listed here:

**DIAGNOSED WITH GDM—WHAT TO DO**

**REFER to OBSTETRICS.** These patients should be followed as high-risk pregnancies.

**CHECK MEDICATIONS** (e.g., ACEIs, statins are teratogenic.) Discharge medications not compatible with pregnancy.

**REFER TO DIETITIAN.**

**REFER TO OPHTHALMOLOGY/OPTOMETRY—GDM high risk for retinopathy or progression.**
1) Retinal eye exams should occur before pregnancy or in the 1st trimester
2) Monitor every trimester and for up to 1 year post-partum as indicated by the degree of retinopathy and recommendations of eye care provider. [B]

**USE INSULIN** for hyperglycemia not controlled with lifestyle. Glycemic control as close to normal as is safely possible, ideally A1C < 6.5%, to reduce the risk of congenital anomalies.* [B]

* Uncontrolled glycemia during gestation is associated with miscarriage, stillbirth, preterm labor and delivery, large birthweight and C-Sec, postnatal hypoglycemia, anencephaly, microcephaly, spinal cord lesions, congenital heart disease, generic anomalies, and cleft palate.

---

### ADA EVIDENCE– GRADING SYSTEM

<table>
<thead>
<tr>
<th>Level of Evidence</th>
<th>Description</th>
</tr>
</thead>
</table>
| **[A]**           | Clear evidence from well-conducted, generalizable randomized controlled trials that are adequately powered, including:  
|                   | • Evidence from a well-conducted multicenter trial  
|                   | • Evidence from a meta-analysis that incorporated quality ratings in the analysis  
|                   | Compelling nonexperimental evidence, i.e., “all or none” rule developed by the Centre for Evidence-Based Medicine at the University of Oxford  
|                   | **Supportive Evidence** from well-conducted randomized controlled trials that are adequately powered, including:  
|                   | • Evidence from a well-conducted trial at one or more institutions  
|                   | • Evidence from a meta-analysis that incorporated quality ratings in the analysis |
| **[B]**           | Supportive evidence from well-conducted cohort studies  
|                   | • Evidence from a well-conducted prospective cohort study or registry  
|                   | • Evidence from a well-conducted meta-analysis of cohort studies  
|                   | **Supportive evidence** from a well-conducted case control study |
| **[C]**           | Supportive evidence from poorly controlled or uncontrolled studies  
|                   | • Evidence from randomized clinical trials with one or more major or three or more minor methodological flaws that could invalidate the results  
|                   | • Evidence from observational studies with high potential for bias (such as case series with comparison with historical controls)  
|                   | • Evidence from case series or case reports  
|                   | Conflicting evidence with the weight of evidence supporting the recommendation |
| **[E]**           | Expert consensus or clinical experience |

The ADA classification system for grading evidence is used to clarify and codify the evidence that forms the basis for the current recommendations. The ratings of [A], [B], or [C] are based on the quality of evidence with [A] recommendations having “the best chance of improving outcomes when applied to the population to which they are appropriate.” An [E] recommendation is a separate category and relies on expert consensus or clinical experience.²

---

¹Adapted from ADA 2018, Diabetes Care Volume 41, Supplement 1, Table 1, January 2018.
Diabetes is a disease that causes high amounts of glucose (sugar) in the blood. It is caused by the body not making enough insulin or not being able to use the insulin it has.

Diabetes can lead to serious health problems including:
- High blood pressure
- Eye/vision problems
- Kidney disease
- Digestive problems
- Amputation of toes or feet
- Heart attacks
- Strokes
- Nerve damage throughout your body
- Skin problems

**SYMPTOMS TO WATCH FOR IF YOU HAVE DIABETES**

**High blood sugar (hyperglycemia) symptoms**
- Thirst
- Frequent urination
- Blurred vision

**Low blood sugar (hypoglycemia) symptoms**
- Shaky
- Sweating
- Fast Heart beat
- Nausea
- Drowsiness
- Coma

What are the causes of high blood sugar?
- Too much food
- Too little diabetes medicine
- Illness
- Stress

What are the causes of low blood sugar?
- Too little food
- Extra exercise
- Too much diabetes medicine or insulin

**What to do if you have symptoms of high blood sugar**
- Be sure to drink plenty of water
- Contact your health care team

**What to do if you have symptoms of low blood sugar**
- Immediately tell someone what is going on.
- If your symptoms are mild you can try to eat or drink something.
- Eat or drink something with sugar in it.
- Contact your health care team if you don't feel better in 15 minutes.
Cholesterol (ko-LESS-tuh-ruhl)

- Cholesterol is a chemical in your blood. LDL is the “bad” cholesterol that can build up and clog your blood vessels, which can cause a heart attack or stroke.
- Most people with diabetes are prescribed medication called “statins” to lower their “bad” cholesterol.
- Your health care provider will check your blood LDL cholesterol level, often once a year, but sometimes less often if you are taking statin medication.

WHAT ELSE SHOULD YOU DO IF YOU HAVE DIABETES?

- Do not smoke.
- Take your medications as directed.
- Control your weight. The best way to maintain a good weight is to eat a healthy diet and exercise more.
  - Be active at least 30 minutes on most days. You can walk, jog, or do exercises in your cell, even during lockdowns.
  - Eat a healthy diet: limit breads and pastas, canteen-junk foods, candy, and ice cream.
- Try to lower stress levels.
- Check your feet every day for cuts, blisters, red spots, and swelling.
- Report any changes in your vision to your health care provider.
- Be sure to get regular check-ups.
- Talk to health care staff about when you should get lab tests including A1C, and when you should get foot, eye, dental, and EKG exams to monitor your condition.

BENEFITS OF EXERCISE IF YOU HAVE DIABETES

- Weight loss and maintenance of normal weight.
- A stronger, healthier heart.
- Improved sleep.
- Improved mood.
- Improved blood pressure, cholesterol, and blood glucose levels.
- May help lower the amount of medication needed to control your blood sugar.
WHY IS FOOT CARE IMPORTANT?
Diabetes can cause you to lose feeling in your feet (feet are numb).

When you have numbness or can’t feel your feet, they can get injured, often without you knowing it, from:

- Something that breaks your skin (such as a cut)
- A deep wound (such as stepping on something sharp)
- Walking barefoot on a hot surface
- Constant pressure in one spot (from a tight shoe)

HOW DO I KEEP MY FEET HEALTHY?
- Check your feet every day.
  - Look for red spots, sores, infected toenails, swelling, cuts, and blisters.
- Wear shoes and socks at all times.
- Wear comfortable shoes that protect your feet and fit well.
- Protect your feet from hot and cold.
- Keep blood flowing to your feet.
  - Put your feet up when sitting.
  - Move your ankles and wiggle your toes throughout the day.
  - Do not cross your legs for long periods of time.
- Wash your feet every day.
  - Dry your feet carefully, especially between the toes.
- Keep the skin of your feet soft and smooth.
  - If you have lotion you can use a thin coat over the tops and bottoms of your feet, but not between your toes.
- Carefully trim your toenails regularly. Ask your health care team for assistance if needed.
- Take care of your diabetes.
  - Work with your health care provider to keep your blood sugar levels in your target range.
- Don’t smoke.
- Be more active.

HOW DO I TREAT FOOT PROBLEMS?
- Talk to your health care provider if you have any foot problems.
EDUCACIÓN PARA EL PACIENTE/CONTROL PERSONAL DEL CASO

DIABETES: LO QUE DEBE SABER

¿QUÉ ES LA DIABETES?

La diabetes es una enfermedad que genera altas cantidades de glucosa (azúcar) en la sangre. Es causada cuando el organismo no produce suficiente insulina o no es capaz de usar la que tiene.

La diabetes puede llevar a problemas severos de salud como:
- Presión arterial alta
- Problemas en ojos/visión
- Enfermedades renales
- Problemas digestivos
- Amputación del pie o de sus dedos

- Ataques cardíacos
- Derrames cerebrales
- Daños a los nervios en todo el cuerpo

SÍNTOMAS QUE DEBE CONTROLAR SI TIENE DIABETES

Síntomas de altos niveles de azúcar en la sangre (hiperglicemia)
- Sed
- Micción frecuente
- Visión borrosa

Síntomas de bajos niveles de azúcar en la sangre (hipoglicemia)
- Tembloroso
- Transpiración
- Latidos cardíacos acelerados
- Náuseas
- Somnolencia
- Coma

- Hambre
- Dolor de cabeza
- Confusión
- De maniático
- Cansado
- Convulsiones

¿Cuáles son las causas de los altos niveles de azúcar en la sangre?
- Demasiada comida
- Poco medicamento para la diabetes
- Enfermedad
- Estrés

¿Cuáles son las causas de los altos niveles de azúcar en la sangre?
- Muy poca comida
- Ejercicio extra
- Demasiado medicamento para la diabetes o insulina

Lo que debe hacer cuando hay síntomas de altos niveles de azúcar en la sangre
- Asegúrese de tomar mucha agua
- Comuníquese con su elenco tratante

Lo que debe hacer cuando hay síntomas de bajos niveles de azúcar en la sangre
- Inmediatamente dile a alguien lo que está pasando.
- Si sus síntomas son leves, puede intentar comer o beber algo.
- Coma o beba algo que contenga azúcar.
- Comuníquese con su elenco tratante si no se siente mejor en los siguientes 15 minutos.
Colesterol
- El colesterol es una sustancia química en su sangre. LDL es el colesterol “malo” que puede acumularse y obstruir sus vasos sanguíneos, lo que puede causar un ataque cardíaco o un derrame cerebral.
- A la mayoría de las personas con diabetes se les prescribe medicamentos llamados “estatinas” para reducir su colesterol “malo.”
- Su médico controlará su nivel de colesterol LDL en la sangre, frecuentemente una vez al año, pero a veces con menos frecuencia si está tomando estatinas.

¿QUÉ MÁS DEBERÍA HACER SI TIENE DIABETES?
- No fume.
- Tome sus medicamentos tal como le sean prescritos.
- Controle su peso. La mejor manera de mantener un buen peso es llevar una dieta sana y ejercitarse más.
  - Haga alguna actividad al menos 30 minutos la mayoría de los días. Puede caminar, trotar o hacer ejercicio en su celda, aún durante un encierro institucional.
  - Lleve una dieta sana: limite los panes y pastas, las comidas chatarra compradas en la cantina, golosinas y helados.
- Intente reducir sus niveles de estrés.
- Revise sus pies diariamente; busque cortadas, ampollas, puntos rojos e inflamación.
- Informe a su médico cualquier cambio en su visión.
- Asegúrese de tener chequeos médicos regulares.
- Hable con el personal médico para saber cuándo debe hacerse pruebas de laboratorio, incluyendo la A1C, y cuándo debe recibir exámenes de los pies, los ojos, los dientes, y un electrocardiograma para controlar su condición.

BENEFICIOS DEL EJERCICIO SI TIENE DIABETES
- Pérdida de peso y mantenimiento de un peso normal.
- Un corazón más fuerte y sano.
- Un sueño mejorado.
- Un estado de ánimo mejorado.
- Una presión arterial mejorada, además de niveles de colesterol y glucosa en la sangre mejorados.
- Podría ayudar a reducir la cantidad de medicamentos necesarios para controlar el azúcar en la sangre.
¿POR QUÉ ES IMPORTANTE EL CUIDADO DE LOS PIES?
La diabetes puede hacer que pierda sensación en sus pies (los pies se entumecen).

Cuando tiene entumecimiento o no puede sentir sus pies, estos se pueden herir y frecuentemente sin que usted se dé cuenta, por:

- Algo que le rompa la piel (como una cortada)
- Una herida profunda (como cuando pisa algo puntiagudo)
- Caminar descalzo sobre una superficie caliente
- Presión constante en algún punto determinado (por un calzado apretado)

¿CÓMO MANTENGO MIS PIES SANOS?

- Revise sus pies diariamente.
  - Busque puntos rojos, llagas, uñas infectadas, inflamación, cortadas y ampollas.
- Siempre use zapatos y calcetines.
- Use zapatos cómodos que protejan sus pies y calcen bien.
- Proteja sus pies del calor y del frío.
- Mantenga la sangre circulando a sus pies.
  - Levante los pies mientras esté sentado.
  - Mueva sus tobillos y los dedos de los pies durante el curso del día.
  - No mantenga sus piernas cruzadas durante largos periodos de tiempo.
- Lave sus pies todos los días.
  - Seque sus pies con cuidado, especialmente entre los dedos.
- Mantenga la piel de sus pies suave y terso.
  - Si tiene loción puede usar una capa delgada sobre las partes superiores e inferiores de sus pies, pero no entre los dedos.
- Con cuidado, córtese las uñas de los dedos de los pies regularmente. Pida ayuda a su elenco tratante de ser necesario.
- Atienda su diabetes.
  - Trabaje con su médico para mantener sus niveles de azúcar en la sangre dentro del rango establecido como meta.
- No fume.
- Realice más actividades.

¿CÓMO TRATO LOS PROBLEMAS DE LOS PIES?
- Hable con su médico si tiene algún problema con los pies.